Articles by Timothy P Flanigan, MD

Participant Characteristics and HIV Risk Behaviors Among Individuals Entering Integrated Buprenorphine/Naloxone and HIV Care

Chaudhry, Amina A; Botsko, Michael; Weiss, Linda; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 56:S14-S21, March 1, 2011.

HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study

Altice, Frederick L; Bruce, R Douglas; Lucas, Gregory M; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 56:S22-S32, March 1, 2011.

Integration of Buprenorphine/Naloxone Treatment into HIV Clinical Care: Lessons From the BHIVES Collaborative

Weiss, Linda; Netherland, Julie; Egan, James E; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 56:S68-S75, March 1, 2011.

Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine

Korthuis, P Todd; Fiellin, David A; Fu, Rongwei; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 56:S83-S90, March 1, 2011.

Testing for HIV, Sexually Transmitted Infections, and Viral Hepatitis in Jails: Still a Missed Opportunity for Public Health and HIV Prevention

Flanigan, Timothy P; Zaller, Nickolas; Beckwith, Curt G; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 55:S78-S83, December 15, 2010.

Reasons for Modification of Generic Highly Active Antiretroviral Therapeutic Regimens Among Patients in Southern India

Kumarasamy, Nagalingeswaran; Vallabhaneni, Snigdha; Cecelia, Anitha J; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 41(1):53-58, January 1, 2006.